|This article is an orphan, as no other articles link to it. Please introduce links to this page from ; try the Find link tool for suggestions. (June 2015)|
|Chemical and physical data|
|Molar mass||348.481 g/mol|
|3D model (JSmol)|
Iferanserin (INN; VEN-309) is a drug which acts as a selective 5-HT2A receptor antagonist. It is under development as an intra-rectal formulation for the treatment of hemorrhoid disease, and as of February 2012, is in phase IIb clinical trials.
- Herold A, Dietrich J, Aitchison R (February 2012). "Intra-anal Iferanserin 10 mg BID for hemorrhoid disease: a prospective, randomized, double-blind, placebo-controlled trial". Clinical Therapeutics. 34 (2): 329–40. PMID 22244049. doi:10.1016/j.clinthera.2011.12.012.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|